# QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

> **NCT06967103** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 238 (estimated)

## Conditions studied

- Breast Cancer
- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Nab-PE

## Key facts

- **NCT ID:** NCT06967103
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2027-05-31
- **Final completion:** 2029-05-30
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06967103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06967103, "QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06967103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*